BATM Advanced Communications Ld Senior management appointments at Adaltis (8439J)

TIDMBVC

RNS Number : 8439J

BATM Advanced Communications Ld

03 July 2017

3 July 2017

BATM Advanced Communications Limited

("BATM" or "the Group")

BATM Appoints Senior Management at Adaltis as it Widens Scope of its Molecular Biology Platform

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce that it is appointing Dr. David Perry MD as Chief Executive Officer of Adaltis S.R.L ("Adaltis") with immediate effect. Adaltis is a majority-owned subsidiary of the Group that manufactures medical diagnostic equipment. This is a new role created within Adaltis as it gears up to take advantage of the advances made within its molecular biology business unit as well as the growing in-vitro diagnostics field. Also, as part of the restructuring of the senior team, the Board of Adaltis is promoting the current General Manager, Marco Spadaciolli, to Chief Operating Officer.

Dr. Perry has more than 20 years' international experience in developing and bringing to global markets new medical devices, and pharmaceutical and biotechnological products across multiple therapy areas, and in small and large companies. Most recently he served as Principal of Lilium Bioscience, a company dedicated to bringing to market novel therapeutic and medical-device products in the areas of biosurgery, orthopedics, regenerative medicine and dermatology.

Prior to this, Dr. Perry headed the global clinical development and medical services departments at Baxter Bioscience as their VP Global Clinical and Medical Affairs. With operations around the world and substantial investment in the development of innovative therapies, Baxter is a major player in several biomedical areas (www.baxter.com). Before Baxter, Dr. Perry established and headed the European clinical research and medical affairs departments for the Philadelphia-based biopharmaceutical company, Cephalon, at their European headquarters in the UK. Prior to that, Dr. Perry held a number of clinical R&D management positions, with increasing scope and level of responsibilities, in a number companies, including Ferring (Copenhagen, Denmark), Roche (Palo Alto, California) and Novo Nordisk (Copenhagen, Denmark). Dr. Perry received his M.D. from the Ben-Gurion University in Israel and did his training at the Hadassah University Hospital in Jerusalem, Israel. Dr. Perry is a fellow of the Royal Society of Medicine and a member of the American Society of Hematology.

Dr. Zvi Marom, CEO of BATM, said: "We are delighted to have David join Adaltis. We believe that Adaltis is maturing to be an important player in the in-vitro diagnostic field and is making the necessary steps to achieve that. We look forward to leveraging David's experience as we take Adaltis to the next stage of its development."

Enquiries:

 
  BATM Advanced Communications 
---------------------------------------  ----------------- 
 Dr Zvi Marom, Chief Executive Officer    [phone] 
---------------------------------------  ----------------- 
 Moti Nagar, Chief Financial Officer 
---------------------------------------  ----------------- 
 
 finnCap 
---------------------------------------  ----------------- 
 Stuart Andrews, Scott Mathieson          [phone] 
---------------------------------------  ----------------- 
 
 Shore Capital 
---------------------------------------  ----------------- 
 Mark Percy, Anita Ghanekar               [phone] 
---------------------------------------  ----------------- 
 
 Luther Pendragon 
---------------------------------------  ----------------- 
 Harry Chathli, Claire Norbury            [phone] 
---------------------------------------  ----------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEANXAELXXEFF

(END) Dow Jones Newswires

July 03, 2017 02:00 ET (06:00 GMT)